1. Introduction {#sec1-ijms-18-00257}
===============

Cardiovascular diseases (CVD) are known to have several causes, including environmental and genetic predispositions. Nutrition is an important environmental factor affecting the risk of developing CVD, and several dietary recommendations have been issued for prevention. However, these recommendations currently do not take into account the fact that individuals respond differently to dietary interventions although this phenomenon is well documented in the literature \[[@B1-ijms-18-00257]\]. For instance, it is recognized that ω-3 fatty acids (FA) from marine sources, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), exert beneficial effects on cardiovascular health owing, among others, to their hypotriglyceridemic properties \[[@B2-ijms-18-00257]\]. However, a large inter-individual variability of the metabolic response to an ω-3 FA supplementation has been observed. In the European FINGEN study, 31% of participants who received a supplement of 1.8 g/day of ω-3 FA for eight weeks did not reduce their plasma triglyceride (TG) levels \[[@B3-ijms-18-00257]\]. Similarly, our research group reported that 29% of all participants of the Fatty Acid Sensor (FAS) Study, who received ω-3 FA supplementation providing 5 g of fish oil per day (1.9--2.2 g of EPA and 1.1 g DHA) over a period of six weeks did not have their plasma TG levels decreased \[[@B4-ijms-18-00257],[@B5-ijms-18-00257]\]. This heterogeneity of the plasma TG response is partly due to genetic factors, including gene-diet interactions \[[@B1-ijms-18-00257],[@B6-ijms-18-00257]\].

Research groups around the world have been studying genes associated with lipid metabolism such as apolipoprotein E and peroxisome proliferator-activated receptor α, and discovered several single nucleotide polymorphisms (SNPs) implicated in this phenomenon \[[@B3-ijms-18-00257],[@B7-ijms-18-00257],[@B8-ijms-18-00257],[@B9-ijms-18-00257],[@B10-ijms-18-00257]\]. However, these variations explain a very small proportion of the variance of the plasma TG levels in response to ω-3 FA supplementation. Since many other associated variations may remain unknown, our team recently conducted a genome-wide association study (GWAS) on subjects of the FAS Study and identified 13 SNPs associated with the plasma TG response \[[@B6-ijms-18-00257]\]. A genetic risk score derived with these SNPs explained 21.5% of the variance of the plasma TG response \[[@B6-ijms-18-00257]\]. Due to linkage disequilibrium (LD) between SNPs in neighbouring genes, it is difficult to discern actual causative SNPs solely with GWAS results. We therefore recently increased the density of markers at TG response-associated loci for the IQ motif-containing J (*IQCJ*), neurexophilin-1 (*NXPH1*), PHD finger protein 17 (*PHF17*) and V-Myb avian myeloblastosis viral oncogene homolog (*MYB*) genes, and found numerous gene-diet interactions and effects of SNPs in the *IQCJ*, *NXPH1* and *MYB* genes on plasma TG levels \[[@B11-ijms-18-00257]\]. However, the underlying mechanisms relating these genes and lipid metabolism remain unclear. *IQCJ* and *NXPH1* are known for their functions in the central and peripheral nervous systems \[[@B12-ijms-18-00257],[@B13-ijms-18-00257],[@B14-ijms-18-00257],[@B15-ijms-18-00257]\]. *PHF17* is involved in mitosis, meiosis and tumor suppression \[[@B16-ijms-18-00257],[@B17-ijms-18-00257]\]. *MYB* regulates various cell functions and plays an important role in hematopoiesis and cancer development \[[@B18-ijms-18-00257],[@B19-ijms-18-00257]\]. Yet, very little associations between these genes and lipid metabolism have been established. Thus, the purpose of this study is to investigate the mechanisms underlying associations between SNPs of candidate genes and TG levels following ω-3 FA supplementation by analyzing gene expression, DNA methylation levels and conducting in silico analyses.

2. Results {#sec2-ijms-18-00257}
==========

[Table 1](#ijms-18-00257-t001){ref-type="table"} shows the baseline characteristics of the participants. In accordance with the inclusion criteria, the average body mass index (BMI) pre- and post-supplementation of all subjects was \>25 kg/m^2^. The average pre-supplementation plasma TG level was above the cut-point value of 1.129 mmol/L based on the last recommendations of the American Heart Association \[[@B2-ijms-18-00257]\].

[Table 2](#ijms-18-00257-t002){ref-type="table"} shows allele frequencies of tagged SNPs. All SNPs were in Hardy-Weinberg equilibrium (HWE). 87% of the genetic variability of *IQCJ*, as well as 85% of *NXPH1*, 96% of *PHF17* and 100% of *MYB* were covered. Most of the SNPs were located in introns, except for three SNPs of *PHF17* that were located in its upstream region, another of *PHF17* that was in the three prime untranslated region (3′ UTR) and one of *MYB* that was in its downstream region.

We searched for possible connections between *IQCJ*, *NXPH1*, *PHF17* and *MYB* and lipid metabolism by conducting in silico analyses. First, RNA splicing analyses revealed two SNPs of *IQCJ*, rs2595260 and rs9827242, showing different affinities to splice sites depending on alleles. Besides, LD analyses indicated no LD between tagged SNPs and other SNPs located in coding or promoter regions. Transcription factor affinity predictions demonstrated the poor affinity of tagged SNPs with transcription factors. We also investigated expression levels of *IQCJ*, *NXPH1*, *PHF17* and *MYB* in specific tissues using the Tissue-specific Gene Expression and Regulation (TiGER) database and the Expression Atlas. *IQCJ* was especially expressed in the brain. Similarly, *NXPH1* was expressed in the brain, but also in the peripheral nervous system. *PHF17* was more ubiquitous. It was mostly expressed in the small intestine, prostate, mammary gland and kidney. *MYB* was expressed in bone marrow, thymus, testis and blood. Analyses of the expression microarrays revealed several effects of genotype on expression levels ([Table 3](#ijms-18-00257-t003){ref-type="table"}). Two SNPs, namely rs10486228 (*NXPH1*) and rs17639758 (*MYB*), were significantly associated with gene expression levels. Three other SNPs, rs17782879 in *IQCJ*, rs11769942 in *NXPH1* and rs11154794 in *MYB*, had marginal but non-significant effects on gene expression. No associations were observed between SNPs in *PHF17* and corresponding gene expression levels.

Significant associations of tagged SNPs from GWAS-associated genes with methylation levels are presented in [Table 4](#ijms-18-00257-t004){ref-type="table"}. A total of 17 significant associations were found with CpG sites and *IQCJ* SNPs. There were also 71 significant associations with *NXPH1* SNPs, 15 with *PHF17* SNPs and seven with *MYB* SNPs. Because of the large number of results and the number of statistical tests computed, we accounted for multiple testing with a false discovery rate. 6 SNPs; rs2044704, rs1962071, rs2595260, rs1449009, rs2621309 and rs61332355, all in *IQCJ*, remained significant after false discovery rate correction.

Spearman correlation coefficients between gene expression and CpG site methylation levels are presented in [Table 5](#ijms-18-00257-t005){ref-type="table"}. Significant correlations between gene expression and methylation levels were obtained with two CpG sites of *IQCJ* (cg15736726 and cg23982461), one of *NXPH1* (cg06328127), three of *PHF17* (cg04482257, cg27628849 and cg17233452) and two of *MYB* (cg01369646 and cg02127509).

Spearman correlation coefficients between TG levels and CpG site methylation levels are presented in [Table 6](#ijms-18-00257-t006){ref-type="table"}. Significant correlations between gene expression and methylation levels were obtained with one CpG site of *IQCJ* (cg09784347), three of *NXPH1* (cg00852549, cg00399951 and cg20378002), four of *PHF17* (cg04482257, cg09863040, cg12832492 and cg01223512) and two of *MYB* (cg18253802 and cg07363239). As to correlations between TG levels and expression levels, the NM_001042705.1 transcript in *IQCJ* was significantly correlated with pre-supplementation TG levels (*p* = 0.0163).

3. Discussion {#sec3-ijms-18-00257}
=============

Our research group recently revealed, in a GWAS, potential SNPs associated with the plasma TG response to ω-3 FA supplementation \[[@B6-ijms-18-00257]\]. We increased the density of markers around GWAS-associated SNPs in the *IQCJ*, *NXPH1*, *PHF17* and *MYB* genes to further verify whether they are associated with plasma TG levels following ω-3 FA supplementation \[[@B11-ijms-18-00257]\]. We found several effects of genotype and gene-diet interactions on plasma TG levels \[[@B11-ijms-18-00257]\]. In the present study, we analysed gene expression and methylation levels, and conducted in silico analyses in order to better understand the potential underlying mechanisms by which *IQCJ*, *NXPH1*, *PHF17* and *MYB* interact with plasma ω-3 FA supplementation to modulate plasma TG levels.

We first observed that two SNPs of *IQCJ*, rs2595260 and rs9827242, had different affinities with splice sites depending on alleles. In our previous study, these SNPs were also found to exert significant gene-diet interactions modulating plasma TG levels \[[@B11-ijms-18-00257]\]. These results therefore indicate that an individual's genotype may possibly affect gene expression of *IQCJ* through the alteration of RNA splicing. Likewise, there was a marginal association between one SNP of *IQCJ*, rs17782879, and its expression levels. We did not find any other substantial results in RNA splicing analyses, nor did we find specific affinities of tagged SNPs with transcription factors. This can be attributable to the location of tagged SNPs. Accordingly, the vast majority of these SNPs are located within introns, whereas regulatory regions are located in splice sites, promoter regions, 3′ UTR, near gene regions (3′ or 5′), and transcribed DNA sequences are located in exons. We therefore searched for other relevant SNPs in LD with tagged SNPs. However, none of these tagged SNPs were in LD with any other SNPs located in coding or promoter regions that have previously been associated with lipid metabolism or with SNPs previously identified in a lipid traits-related GWAS.

Additionally, according to in silico analyses, all candidate genes were poorly expressed in tissues related to lipid metabolism, such as adipose tissue, liver or pancreas. These observations are coherent with known functions of these genes. In fact, very few links between *IQCJ*, *NXPH1*, *PHF17*, *MYB* and lipid metabolism have been made in the past. *IQCJ* is bound to the schwannomin-interacting protein 1 (*SCHIP1*) to form another transcriptional unit (*IQCJ-SCHIP1*) \[[@B12-ijms-18-00257]\]. *IQCJ-SCHIP1* plays roles in the function of initial axon segments and nodes of Ranvier, which are essential structures to saltatory conduction in the central and peripheral nervous systems \[[@B13-ijms-18-00257]\]. According to the results of a GWAS conducted on participants of the Genetics of Lipid Lowering Drugs and Diet Network (*GOLDN*) study, which aimed to study the effect of lipid-lowering therapy to fenofibrate on the response of various lipid traits, *IQCJ-SCHIP1* may actually be associated with TG levels as well as very-low-density lipoprotein (VLDL) particle clearance \[[@B20-ijms-18-00257]\]. VLDL particle clearance is an important determinant of blood TG levels \[[@B21-ijms-18-00257]\]. Dysfunctional VLDL hydrolysis can increase TG-rich lipoprotein remnant particles synthesis, which is associated with an increased risk of atherosclerosis \[[@B21-ijms-18-00257],[@B22-ijms-18-00257],[@B23-ijms-18-00257]\]. In the same GWAS, several SNPs of *NXPH1* were associated with type 2 diabetes, blood pressure and plasma LDL-cholesterol, HDL-cholesterol, TG as well as C-reactive protein levels \[[@B20-ijms-18-00257]\]. In another study, *NXPH1* was associated with type 2 diabetes traits among a population of obese Hispanic children \[[@B24-ijms-18-00257]\]. *NXPH1* is known to code for a neuronal glycoprotein that binds to α-neurexin to regulate neuronal function, neurotransmission, signalisation and various cell interactions \[[@B14-ijms-18-00257],[@B15-ijms-18-00257],[@B25-ijms-18-00257]\]. *PHF17* codes for the Jade-1 protein. This protein interacts with histone acetyltransferase HBO1 and promotes histone acetylation in chromatin to regulate DNA replication and gene transcription \[[@B16-ijms-18-00257],[@B26-ijms-18-00257],[@B27-ijms-18-00257]\]. *MYB* encodes the c-Myb transcription factor, which regulates the expression of a wide variety of genes involved in cell function \[[@B18-ijms-18-00257]\]. *MYB* has been reported to be associated with the development of CVD, intracellular accumulation of lipid, differentiation of mesenchymal stem cells from adipose tissue, intestinal absorption of nutrients and possibly BMI \[[@B28-ijms-18-00257],[@B29-ijms-18-00257],[@B30-ijms-18-00257],[@B31-ijms-18-00257]\]. The c-Myb protein is expressed in the vascular smooth muscle and it is induced by homocysteine, while high levels of homocysteine are recognized as an independent CVD risk factor \[[@B28-ijms-18-00257],[@B32-ijms-18-00257]\].

Moreover, we tested whether tagged SNPs are associated with pre-supplementation methylation levels and observed several significant associations. Many tagged SNPs that were marginally or significantly associated with plasma TG levels and the plasma TG response to ω-3 FA supplementation in our previous study appear now to be significantly associated with methylation levels as well. This is particularly true for *IQCJ* and *NXPH1*. Mostly all SNPs of *IQCJ* showing significant gene-diet interactions are associated with one particular mutual CpG site (cg16975599). This CpG site is close to rs548649590, which was not tested for associations with plasma TG levels in our previous study. This SNP is not in LD with any SNP previously associated with plasma TG levels either. Furthermore, we accounted for multiple testing with a false discovery rate and found out that the strongest associations were in *IQCJ*. None of the SNP of *MYB* that was previously found to exert effects of gene-diet interactions on plasma TG levels was associated with methylation levels at CpG sites. None was in LD with any SNPs associated with CpG sites either. These outcomes suggest that the modulation of plasma TG levels through genes revealed by GWAS, especially *IQCJ* and *NXPH1*, may be regulated by DNA methylation, which is here influenced by genotype. As DNA methylation is strongly related to gene expression, individuals' genotype could directly upregulate or downregulate gene expression \[[@B33-ijms-18-00257],[@B34-ijms-18-00257]\]. Gene expression analyses also support this rationale. Indeed, gene expression of *IQCJ*, *NXPH1* and *MYB* appeared to be affected by DNA variations within these genes. It was also shown to be influenced by TG levels and methylation levels in *IQCJ*, *NXPH1*, *PHF17* and *MYB*.

4. Materials and Methods {#sec4-ijms-18-00257}
========================

4.1. Study Population {#sec4dot1-ijms-18-00257}
---------------------

A total of 254 participants were recruited to participate in the FAS Study between September 2009 and December 2011 in the Quebec City metropolitan area through advertisements in local newspapers and electronic messages sent to university students and employees. Participants had to be between 18 and 50 years of age, to be non-smokers and to have a BMI between 25 and 40 kg/m^2^. Candidates were excluded if they had taken fish oil supplements for at least six months prior to the beginning of the study or if they were suffering from any thyroid or metabolic disorders such as diabetes, hypertension, dyslipidemia or coronary heart disease. Statistical analyses were conducted on 210 subjects who completed the supplementation period. Data on plasma TG levels were missing for two of them, leaving 208 individuals in the final study sample.

4.2. Study Design and Diets {#sec4dot2-ijms-18-00257}
---------------------------

The complete study design and diets have been reported in previous papers \[[@B6-ijms-18-00257],[@B11-ijms-18-00257]\]. Briefly, participants followed a run-in period of two weeks, wherein a trained registered dietitian gave dietary instructions for them to achieve the recommendations from Canada's Food Guide, to ensure constant dietary intake and to keep a stable body weight throughout the protocol. Subsequently, they received ω-3 FA capsules (Ocean Nutrition, Dartmouth, NS, Canada) in a sufficient amount to cover the six-week supplementation protocol. Each capsule contained 1 g of fish oil concentrate. They had to take five capsules a day, providing 3 g of ω-3 FA, including 1.9--2.2 g of EPA and 1.1 g of DHA. They had to report any deviation from the protocol as well as experienced side effects. They also had to note their alcohol and fish consumption if any. Finally, oral and written dietary instructions were given to participants before each phase.

4.3. Anthropometric Measurements {#sec4dot3-ijms-18-00257}
--------------------------------

Height and body weight were measured before the run-in period, as well as before and after the intervention following the recommendations of the Airlie Conference. BMI (kg/m^2^) was obtained by dividing weight (kg) by the squared height (m^2^).

4.4. Laboratory Methods {#sec4dot4-ijms-18-00257}
-----------------------

### 4.4.1. Plasma Lipids {#sec4dot4dot1-ijms-18-00257}

Methods to measure plasma lipids have previously been detailed \[[@B6-ijms-18-00257],[@B11-ijms-18-00257]\]. Briefly, blood samples were collected after a 12 h overnight fast and 48 h alcohol abstinence. Blood samples were taken before the run-in period to verify whether individuals were presenting any metabolic disorders. Blood samples of remaining participants were taken before and after the ω-3 FA supplementation period. Enzymatic assays were used to measure plasma total cholesterol and TG concentrations \[[@B35-ijms-18-00257],[@B36-ijms-18-00257]\].

### 4.4.2. SNP Selection and Genotyping {#sec4dot4dot2-ijms-18-00257}

SNPs were identified using the International HapMap Project SNP database, based on the National Center for Biotechnology information (NCBI) B36 assembly Data Rel 28, phase II + III, built 126. The Gene Tagger procedure in Haploview v4.2 was used to identify tagging SNPs with a minor allele frequency (MAF) \>5% and pairwise tagging (*r*^2^ ≥ 0.80) located in gene regions and surrounding regions (2 kb upstream and downstream gene). The mean LD (*r*^2^) between SNPs was 0.96 for *IQCJ*, 0.96 for *NXPH1*, 0.97 for *PHF17* and 0.95 for *MYB*. SNPs were selected in a way to cover ≥85% of all common variations (MAF \> 5%). The GenElute Gel Extraction Kit (Sigma-Aldrich Co., St. Louis, MO, USA) was used to extract genomic DNA (gDNA) from blood samples. Tagged SNPs were genotyped using TaqMan technology: 2.5 µL of each gDNA (40 ng/µL) and 2.5 µL of OpenArray Genotyper Master Mix (Life Technologies, Carlsbad, CA, USA) were mixed in a 384-well plate with validated primers and loaded onto genotyping plates using the QuantStudio^TM^ 12K Flex OpenArray^®^ AccuFill^TM^ System (Life Technologies). The QuantStudio^TM^ 12K Flex Real-Time PCR System (Life Technologies) was used for genotyping. Finally, TaqMan Genotyper v1.3 (Life Technologies) was used to call genotypes and export data.

### 4.4.3. In Silico Analyses {#sec4dot4dot3-ijms-18-00257}

RNA splicing analyses were performed for each tagged SNP using ESEfinder and Berkeley Drosophilia Genome Project splice site prediction tools \[[@B37-ijms-18-00257],[@B38-ijms-18-00257],[@B39-ijms-18-00257]\]. LD between tagged and other non-tagged SNPs was assessed using SNP Annotation and Proxy Search (SNAP) with an *r*^2^ threshold of 0.8 and a distance limit of 500 kb \[[@B40-ijms-18-00257]\]. LD was calculated with the Northern Europeans from Utah (CEU) population. We also used the Transcription factor Affinity Prediction (TRAP) web tools for single sequences to measure the possible transcription factor binding affinities to tagged SNP regions in the presence or absence of SNPs \[[@B41-ijms-18-00257],[@B42-ijms-18-00257],[@B43-ijms-18-00257]\]. Furthermore, we used the TiGER database as well as the Expression Atlas to evaluate expression levels of our genes of interest in different tissues \[[@B44-ijms-18-00257],[@B45-ijms-18-00257],[@B46-ijms-18-00257],[@B47-ijms-18-00257]\].

### 4.4.4. Transcriptomic Gene Expression Analyses {#sec4dot4dot4-ijms-18-00257}

The expression of transcripts associated with the four genes of interest was measured in peripheral blood mononuclear cells of the first 30 participants of the FAS study to complete the intervention via the Human-6 v3 Expression BeadChips (Illumina, San Diego, CA, USA). Transcriptomic analyses have previously been detailed \[[@B5-ijms-18-00257]\].

### 4.4.5. DNA Methylation Analyses {#sec4dot4dot5-ijms-18-00257}

DNA methylation analyses were conducted on blood cells of 35 participants of the FAS study. Bisulfite conversion was made on 1 µg of DNA. Quantitative DNA methylation analyses were conducted at the Génome Québec Innovation Centre and McGill University (Montreal, QC, Canada). The Infinium HumanMethylation450 BeadChip (Illumina) was used for methylation sites coverage following the manufacturer's instructions. CpG site positions were located according to genome build 37. The GenomeStudio software version 2011.1 (Illumina) as well as the methylation module were used to visualise and analyse methylation data. The ratio of signal intensity of the methylated alleles to the sum of methylated and unmethylated intensity signals of the alleles (β value = C/(T + C)) was used to estimate methylation levels (β value). Internal control probe pairs was applied for data correction. CpG sites were extracted using the GenomeStudio Methylation Module. A total of 10 CpG sites in *IQCJ*, 43 in *NXPH1*, 34 in *PHF17* and 24 in *MYB* were used.

### 4.4.6. Statistical Analyses {#sec4dot4dot6-ijms-18-00257}

The ALLELE procedure in SAS Genetics Statistical Software v9.3 (SAS Institute, Cary, NC, USA) was used to assess genotype distribution for any deviation from the HWE and to calculate the MAF. All other statistical analyses were performed in SAS v9.2. Normal distribution was evaluated with the box-plot, skewness and kurtosis ranges. Abnormally distributed variables were log~10~-transformed. Common genotype homozygotes, heterozygotes and rare genotype homozygotes were analysed separately in an additive model. However, rare genotype homozygotes showing a genotype frequency \<5% were merged with heterozygotes for statistical analyses in a dominant model. The GLM procedure adjusted for age, sex and BMI was used to test for associations between pre-supplementation methylation levels and tagged SNPs for each gene independently. It was also used to test for the effects of genotype on gene expression levels using again age, sex and BMI as co-variates in the model. The MULTTEST procedure was then used to account for multiple testing controlling for false discovery rate. The CORR procedure adjusted for age, sex and BMI was used to correlate gene expression and methylation levels on 29 subjects using Spearman rank correlation. It was also used to correlate TG levels with gene expression and methylation levels on respectively 30 and 35 subjects using Spearman rank correlation. Statistical significance was fixed at *p* ≤ 0.05.

4.5. Consent {#sec4dot5-ijms-18-00257}
------------

The study was approved by the Université Laval and Centre hospitalier universitaire (CHU) de Québec ethics committees and was performed in accordance with the principles of the Declaration of Helsinki. All participants provided written and informed consent. This study is derived from a registered clinical trial (NCT01343342).

5. Conclusions {#sec5-ijms-18-00257}
==============

Results of the present study demonstrate that the response of plasma TG to an ω-3 FA supplementation may be modulated through the effect of DNA methylation on expression levels of genes previously identified in a GWAS by our group (*IQCJ*, *NXPH1*, *PHF17* and *MYB*). Further research is needed to provide a better understanding of the relationship between these genes and TG metabolism.
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###### 

Characteristics of the study sample before and after supplementation.

  Characteristics       Before Supplementation   After Supplementation   *p* Value ^a^
  --------------------- ------------------------ ----------------------- ---------------
  Study population, n   210                      208                     \-
  Age, years            30.8 ± 8.7               \-                      \-
  Weight, kg ^b^        81.3 ± 13.9              81.6 ± 14.2             0.0009
  BMI, kg/m^2^ ^b^      27.8 ± 3.7               27.9 ± 3.8              0.005
  TG, mmol/L ^b^        1.21 ± 0.63              1.02 ± 0.52             \<0.0001

Values are means ± standard deviation (SD) unless otherwise indicated; *p* Values were obtained using the Student's *t*-test (TTEST) procedure (SAS Genetics v9.2); BMI = body mass index; TG = triglycerides; ^a^ *p* \< 0.05 was considered significant; ^b^ *p* Values are for log10-transformed values.

ijms-18-00257-t002_Table 2

###### 

Selected polymorphisms in candidate genes from the genome-wide association study (GWAS) of the Fatty Acid Sensor (FAS) study (*n* = 210 individuals).

  Gene             dbSNP No.       Sequence         Location                 Genotype Frequency                                
  ---------------- --------------- ---------------- ------------------------ ------------------------ ------------------------ ------------------------
  *IQCJ*           rs12497650      TTT\[C/T\]ATTG   Intron                   C/C (*n* = 95) 0.4524    C/T (*n* = 96) 0.4571    T/T (*n* = 19) 0.0905
  rs4501157        ACA\[G/T\]TAA   Intron           G/G (*n* = 29) 0.1388    G/T (*n* = 89) 0.4258    T/T (*n* = 91) 0.4354    
  rs13091349       TCT\[C/T\]CTC   Intron           C/C (*n* = 147) 0.7000   C/T (*n* = 56) 0.2667    T/T (*n* = 7) 0.0333     
  rs2044704        TTT\[C/G\]TAG   Intron           C/C (*n* = 20) 0.0952    C/G (*n* = 68) 0.3238    G/G (*n* = 122) 0.5810   
  rs1962071        AGC\[A/C\]GCC   Intron           A/A (*n* = 116) 0.5524   A/C (*n* = 74) 0.3524    C/C (*n* = 20) 0.0952    
  rs7634829        TGT\[A/G\]TAA   Intron           A/A (*n* = 68) 0.3238    A/G (*n* = 101) 0.4810   G/G (*n* = 41) 0.1952    
  rs2621294        TGC\[A/G\]AAG   Intron           A/A (*n* = 85) 0.4067    A/G (*n* = 90) 0.4306    G/G (*n* = 34) 0.1627    
  rs6800211        AGG\[C/T\]GTC   Intron           C/C (*n* = 104) 0.4952   C/T (*n* = 90) 0.4286    T/T (*n* = 16) 0.0762    
  rs17782879       TCC\[A/G\]TAT   Intron           A/A (*n* = 20) 0.0952    A/G (*n* = 88) 0.4190    G/G (*n* = 102) 0.4857   
  rs1868414        CTG\[C/T\]GCC   Intron           C/C (*n* = 100) 0.4785   C/T (*n* = 81) 0.3876    T/T (*n* = 28) 0.1340    
  rs2595260        AGG\[C/T\]ATC   Intron           C/C (*n* = 125) 0.5952   C/T (*n* = 66) 0.3143    T/T (n = 19) 0.0905      
  rs6763890        ATG\[A/T\]CTT   Intron           A/A (*n* = 28) 0.1340    A/T (*n* = 85) 0.4067    T/T (*n* = 96) 0.4593    
  rs9827242        TCA\[C/T\]AGT   Intron           C/C (*n* = 5) 0.0238     C/T (*n* = 68) 0.3238    T/T (*n*=137) 0.6524     
  rs1449009 ^a^    CAA\[C/T\]ATT   Intron           A/A (*n* = 110) 0.5238   A/G (*n* = 77) 0.3667    G/G (*n* = 23) 0.1095    
  rs2621309 ^a^    TTT\[C/G\]CTT   Intron           C/C (*n* = 114) 0.5429   C/G (*n* = 72) 0.3429    G/G (*n* = 21) 0.1000    
  rs61332355 ^a^   AGG\[A/C\]AAT   Intron           A/A (*n* = 6) 0.0286     A/C (*n* = 64) 0.3048    C/C (*n* = 140) 0.6667   
  *NXPH1*          rs6956210       TTC\[C/T\]TTT    Intron                   C/C (*n* = 14) 0.0667    C/T (*n* = 71) 0.3381    T/T (*n* = 125) 0.5952
  rs2107779        ATG\[C/T\]TGA   Intron           C/C (*n* = 69) 0.3286    C/T (*n* = 94) 0.4476    T/T (*n* = 47) 0.2238    
  rs10273195       CTG\[A/T\]GGC   Intron           A/A (*n* = 134) 0.6381   A/T (*n* = 68) 0.3238    T/T (*n* = 8) 0.0381     
  rs12216689       TGA\[A/C\]TGA   Intron           A/A (*n* = 108) 0.5143   A/C (*n* = 85) 0.T/T8    C/C (*n* = 17) 0.0810    
  rs6963644        TGC\[A/G\]TTT   Intron           A/A (*n* = 0) 0          A/G (*n* = 32) 0.1524    G/G (*n* = 178) 0.8476   
  rs17150341       AGG\[C/T\]ATT   Intron           C/C (*n* = 102) 0.4857   C/T (*n* = 88) 0.4190    T/T (*n* = 20) 0.0952    
  rs1013868        TTC\[A/G\]CTG   Intron           C/C (*n* = 93) 0.4429    C/T (*n* = 95) 0.4524    T/T (*n* = 22) 0.1048    
  rs12537067       CTA\[A/G\]CTC   Intron           A/A (*n* = 1) 0.0048     A/G (*n* = 33) 0.1571    G/G (*n* = 176) 0.8381   
  rs4318981        CAT\[C/T\]ATA   Intron           C/C (*n* = 31) 0.1476    C/T (*n* = 88) 0.4190    T/T (*n* = 91) 0.4333    
  rs17153997       GTG\[C/T\]GTA   Intron           C/C (*n* = 73) 0.3493    C/T (*n* = 92) 0.4402    T/T (*n* = 44) 0.2105    
  rs7801099        AAC\[A/G\]ACA   Intron           A/A (*n* = 64) 0.G/T8    A/G (*n* = 105) 0.5000   G/G (*n* = 41) 0.1952    
  rs4725120        ATA\[A/G\]AAG   Intron           A/A (*n* = 47) 0.2238    A/G (*n* = 99) 0.4714    G/G (*n* = 64) 0.3048    
  rs1859275        GTG\[A/G\]CTA   Intron           A/A (*n* = 30) 0.1435    A/G (*n* = 87) 0.4163    G/G (*n* = 92) 0.4402    
  rs10238726       CTC\[A/G\]TTC   Intron           A/A (*n* = 102) 0.4857   A/G (*n* = 84) 0.4000    G/G (*n* = 24) 0.1143    
  rs1012960        GTT\[A/T\]CTT   Intron           A/A (*n* = 46) 0.2190    A/T (*n* = 118) 0.5619   T/T (*n* = 46) 0.2190    
  rs11767429       ACA\[A/G\]GAG   Intron           A/A (*n* = 106) 0.5048   A/G (*n* = 82) 0.3905    G/G (*n* = 22) 0.A/T8    
  rs4333500        AAG\[G/T\]TGG   Intron           G/G (*n* = 74) 0.3524    G/T (*n* = 105) 0.5000   T/T (*n* = 31) 0.1476    
  rs7793115        GGA\[A/G\]GAG   Intron           A/A (*n* = 2) 0.0096     A/G (*n* = 37) 0.1770    G/G (*n* = 170) 0.8134   
  rs7799856        CAA\[A/C\]AAA   Intron           A/A (*n* = 76) 0.3619    A/C (*n* = 88) 0.4190    C/C (*n* = 46) 0.2190    
  rs7806226        ATA\[A/C\]TAT   Intron           A/A (*n* = 154) 0.7333   A/C (*n* = 46) 0.2190    C/C (*n* = 10) 0.0476    
  rs13221144       CCT\[C/T\]ACG   Intron           C/C (*n* = 11) 0.0524    C/T (*n* = 75) 0.3571    T/T (*n* = 124) 0.5905   
  rs17406479       TTG\[G/T\]TTT   Intron           G/G (*n* = 136) 0.6476   G/T (*n* = 69) 0.3286    T/T (*n* = 5) 0.0238     
  rs10486228       AAA\[C/T\]TGA   Intron           C/C (*n* = 6) 0.0286     C/T (*n* = 64) 0.3048    T/T (*n* = 140) 0.6667   
  rs17154569       TCT\[A/G\]AGA   Intron           A/A (*n* = 140) 0.6699   A/G (*n* = 64) 0.3062    G/G (*n* = 5) 0.0239     
  rs4141002        CAC\[C/T\]TGT   Intron           C/C (*n* = 161) 0.7667   C/T (*n* = 46) 0.2190    T/T (*n* = 3) 0.0143     
  rs7805772        GAG\[A/G\]TCC   Intron           A/A (*n* = 141) 0.6746   A/G (*n* = 56) 0.2679    G/G (*n* = 12) 0.0574    
  rs2349780        ACA\[A/G\]TGG   Intron           A/A (*n* = 76) 0.3619    A/G (*n* = 108) 0.5143   G/G (*n* = 26) 0.1238    
  rs2107474        CTT\[C/G\]AAC   Intron           C/C (*n*= 71) 0.3381     C/G (*n*= 100) 0.4762    G/G (*n*= 39) 0.1857     
  rs11769942       TTC\[C/T\]GAC   Intron           C/C (*n*= 84) 0.4000     C/T (*n*= 95) 0.4524     T/T (*n*= 31) 0.1476     
  rs6952383        CTA\[A/T\]TCT   Intron           A/A (*n*= 171) 0.8143    A/T (*n*= 36) 0.1714     T/T (*n*= 3) 0.0143      
  rs6974252        GTA\[A/G\]TTG   Intron           A/A (*n*= 4) 0.0190      A/G (*n*= 51) 0.2429     G/G (*n*= 155) 0.7381    
  rs10265408       CTG\[C/G\]ATG   Intron           C/C (*n*= 110) 0.5263    C/G (*n*= 83) 0.3971     G/G (*n*= 16) 0.0766     
  rs2189904        TAC\[C/T\]TTT   Intron           C/C (*n*= 93) 0.4429     C/T (*n*= 95) 0.4524     T/T (*n*= 22) 0.1048     
  rs2057862        AGA\[C/G\]TGT   Intron           C/C (*n*= 38) 0.1818     C/G (*n*= 95) 0.4545     G/G (*n*= 76) 0.3636     
  *PHF17*          rs2217023       GCA\[C/G\]ATG    nearGene-5′              C/C (*n*= 10) 0.0478     C/G (*n*= 61) 0.2919     G/G (*n*= 138) 0.6603
  rs4975270        TAC\[A/G\]CAT   Intron           A/A (*n*= 76) 0.3619     A/G (*n*= 88) 0.4190     G/G (*n*= 46) 0.2190     
  rs11722830       CTT\[A/G\]TGG   Intron           A/A (*n*= 8) 0.0381      A/G (*n*= 73) 0.3476     G/G (*n*= 129) 0.6143    
  rs12505447       CCT\[C/T\]GGG   Intron           C/C (*n*= 138) 0.6571    C/T (*n*= 65) 0.3095     T/T (*n*= 7) 0.0333      
  rs6534704        GTA\[A/T\]CCT   Intron           A/A (*n*= 3) 0.0143      A/T (*n*= 26) 0.1238     T/T (*n*= 181) 0.8619    
  rs13148510       CAA\[C/G\]AGC   3′ UTR           C/C (*n*= 193) 0.9190    C/G (*n*= 17) 0.0810     G/G (*n*= 0) 0           
  rs13143771       ATA\[C/T\]AGT   nearGene-5′      C/C (*n*= 19) 0.0905     C/T (*n*= 81) 0.3857     T/T (*n*= 110) 0.5238    
  rs13142964       TAA\[C/G\]AAC   nearGene-5′      C/C (*n*= 179) 0.8524    C/G (*n*= 31) 0.1476     G/G (*n*= 0) 0           
  *MYB*            rs9321493       GTA\[C/T\]ACT    Intron                   C/C (*n*= 68) 0.3238     C/T (*n*= 97) 0.4619     T/T (*n*= 45) 0.2143
  rs11154794       AGC\[C/T\]TCC   Intron           C/C (*n*= 3) 0.0143      C/T (*n*= 47) 0.2238     T/T (*n*= 160) 0.7619    
  rs210798         GAA\[G/T\]TCC   Intron           G/G (*n*= 75) 0.3571     G/T (*n*= 95) 0.4524     T/T (*n*= 40) 0.1905     
  rs210936         CTT\[C/T\]TCC   nearGene-3′      A/A (*n*= 60) 0.2857     A/G (*n*= 98) 0.4667     G/G (*n*= 52) 0.2476     
  rs7757388        ATA\[A/G\]AAG   Intron           A/A (*n*= 148) 0.7081    A/G (*n*= 55) 0.2632     G/G (*n*= 6) 0.0287      
  rs210962         AGA\[C/T\]CCT   Intron           C/C (*n*= 125) 0.5981    C/T (*n*= 68) 0.3254     T/T (*n*= 16) 0.0766     
  rs17639758       GTA\[A/G\]CAT   Intron           A/A (*n*= 0) 0           A/G (*n*= 11) 0.0524     G/G (*n*= 199) 0.9476    
  rs1013891        TAC\[A/G\]GCA   Intron           A/A (*n*= 26) 0.1238     A/G (*n*= 94) 0.4476     G/G (*n*= 90) 0.4286     
  rs2179308        GGT\[A/G\]TTG   Intron           A/A (*n*= 54) 0.2571     A/G (*n*= 106) 0.5048    G/G (*n*= 50) 0.2381     

Genotype frequency was obtained using the ALLELE procedure (SAS Genetics v9.3); dbSNP = Single- Nucleotide Polymorphism (SNP) Database; ^a^ GWAS hit identified in the FAS study.
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###### 

Effects of genotype on the expression of transcripts associated with the *IQCJ*, *NXPH1*, *PHF17* and *MYB* genes (*n* = 30 individuals).

  Gene         SNP             Transcript       *p* Value
  ------------ --------------- ---------------- -----------
  *IQCJ*       rs17782879      NM_001042706.1   0.06
  *NXPH1*      rs10486228      NM_152745.2      0.01
  rs11769942   NM_152745.2     0.07             
  *MYB*        rs11154794 \*   NM_005375.2      0.09
  rs17639758   NM_005375.2     0.02             

The General Linear Model (GLM) procedure (SAS v9.2) adjusted for age, sex and body mass index was used to test for the effects of genotype on the expression of transcripts; SNP = Single- Nucleotide Polymorphism; \* Heterozygotes merged with rare homozygotes (dominant model).
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###### 

Significant associations of tagged single-nucleotide polymorphisms (SNPs) from genome-wide association study (GWAS)-associated genes with pre-supplementation methylation levels (*n* = 35 individuals).

  Gene                 SNP                CpG Site ^a^       Position           *p* Value ^b^
  -------------------- ------------------ ------------------ ------------------ ---------------
  *IQCJ*               rs4501157          cg09784347         CHR 3, 158786963   0.0457
  cg17255703           CHR 3, 158787141   0.0077                                
  cg10461878           CHR 3, 158904717   0.0035                                
  rs2044704 ^c^        cg16975599         CHR 3, 158962761   0.0001 \*          
  rs1962071 ^c^        cg16975599         CHR 3, 158962761   0.0004 \*          
  rs7634829            cg17255703         CHR 3, 158787141   0.0025             
  rs2621294            cg26659665         CHR 3, 158786242   0.0238             
  cg10461878           CHR 3, 158904717   0.0301                                
  cg12919294           CHR 3, 158962196   0.0152                                
  rs17782879 ^c^       cg16975599         CHR 3, 158962761   0.0362             
  rs1868414 ^c^        cg16975599         CHR 3, 158962761   0.0086             
  rs2595260 ^c^        cg16975599         CHR 3, 158962761   0.0001 \*          
  rs9827242 ^c,d^      cg23982461         CHR 3, 158955027   0.0077             
  cg16975599           CHR 3, 158962761   0.0056                                
  rs1449009 ^c,e^      cg16975599         CHR 3, 158962761   0.0001 \*          
  rs2621309 ^c,e^      cg16975599         CHR 3, 158962761   0.0001 \*          
  rs61332355 ^c,d,e^   cg16975599         CHR 3, 158962761   0.0002 \*          
  *NXPH1*              rs6956210          cg06328127         CHR 7, 8469546     0.0089
  cg11642377           CHR 7, 8480779     0.0048                                
  rs2107779 ^c^        cg20378002         CHR 7, 8477029     0.0109             
  cg08897422           CHR 7, 8666902     0.0059                                
  cg21001050           CHR 7, 8791686     0.0006                                
  rs12216689 ^c^       cg00852549         CHR 7, 8473457     0.0120             
  cg17278735           CHR 7, 8476834     0.0127                                
  cg01933308           CHR 7, 8483569     0.0388                                
  cg13611822           CHR 7, 8483710     0.0404                                
  rs6963644            cg07462540         CHR 7, 8473279     0.0375             
  cg00852549           CHR 7, 8473457     0.0327                                
  cg06444755           CHR 7, 8473990     0.0266                                
  cg20378002           CHR 7, 8477029     0.0123                                
  cg23075337           CHR 7, 8481460     0.0051                                
  cg22287800           CHR 7, 8634300     0.0245                                
  cg08897422           CHR 7, 8666902     0.0259                                
  rs1013868 ^c^        cg24785946         CHR 7, 8473234     0.0266             
  cg00852549           CHR 7, 8473457     0.0103                                
  cg09225457           CHR 7, 8481460     0.0495                                
  rs4318981            cg06981279         CHR 7, 8477156     0.0452             
  cg07511564           CHR 7, 8481036     0.0211                                
  cg01933308           CHR 7, 8483569     0.0474                                
  cg02614372           CHR 7, 8486611     0.0261                                
  rs7801099            cg24785946         CHR 7, 8473234     0.0238             
  cg00852549           CHR 7, 8473457     0.0095                                
  cg09225457           CHR 7, 8479893     0.0289                                
  rs4725120            cg06981279         CHR 7, 8477156     0.0425             
  cg01994275           CHR 7, 8480586     0.0122                                
  rs1859275            cg22339356         CHR 7, 8473385     0.0153             
  cg01354961           CHR 7, 8473462     0.0148                                
  cg07511564           CHR 7, 8481036     0.0247                                
  rs1012960            cg07462540         CHR 7, 8473279     0.0437             
  cg00852549           CHR 7, 8473457     0.0282                                
  cg06981279           CHR 7, 8477156     0.0093                                
  rs11767429 ^c^       cg00288806         CHR 7, 8476521     0.0287             
  cg21001050           CHR 7, 8791686     0.0252                                
  rs4333500            cg00852549         CHR 7, 8473457     0.0479             
  cg12597389           CHR 7, 8482235     0.0391                                
  rs7799856            cg24785946         CHR 7, 8473234     0.0343             
  cg00399951           CHR 7, 8476098     0.0378                                
  cg00288806           CHR 7, 8476521     0.0270                                
  cg21001050           CHR 7, 8791686     0.0470                                
  rs13221144           cg08897422         CHR 7, 8666902     0.0448             
  rs7805772 ^c^        cg12597389         CHR 7, 8482235     0.0445             
  rs2349780 ^c^        cg19469357         CHR 7, 8474830     0.0264             
  cg06056929           CHR 7, 8476128     0.0017                                
  cg00288806           CHR 7, 8476521     0.0167                                
  cg15285250           CHR 7, 8482107     0.0229                                
  rs11769942           cg09225457         CHR 7, 8479893     0.0113             
  rs2057862            cg02124383         CHR 7, 8475198     0.0396             
  cg20378002           CHR 7, 8477029     0.0017                                
  cg08897422           CHR 7, 8666902     0.0247                                
  cg21001050           CHR 7, 8791686     0.0048                                
  rs10265408           cg06328127         CHR 7, 8469546     0.0327             
  rs10273195 ^d^       cg06981279         CHR 7, 8477156     0.0287             
  cg06335867           CHR 7, 8482325     0.0467                                
  cg21806015           CHR 7, 8483249     0.0243                                
  rs12537067 ^d^       cg01994275         CHR 7, 8480586     0.0466             
  cg06328127           CHR 7, 8469546     0.0346                                
  rs7793115 ^d^        cg22339356         CHR 7, 8473385     0.0435             
  rs17406479 ^d^       cg26170604         CHR 7, 8482614     0.0143             
  rs10486228 ^d^       cg20378002         CHR 7, 8477029     0.0435             
  cg21001050           CHR 7, 8791686     0.0098                                
  rs17154569 ^d^       cg13611822         CHR 7, 8483710     0.0447             
  cg06328127           CHR 7, 8469546     0.0298                                
  rs6952383 ^d^        cg00852549         CHR 7, 8473457     0.0464             
  cg20378002           CHR 7, 8477029     0.0007                                
  cg23075337           CHR 7, 8481460     0.0102                                
  cg10443049           CHR 7, 8481537     0.0337                                
  cg12597389           CHR 7, 8482235     0.0331                                
  cg01933308           CHR 7, 8483569     0.0137                                
  *PHF17*              rs4975270          cg19120496         CHR 4, 129731335   0.0493
  cg09164670           CHR 4, 129731835   0.0106                                
  cg26347359           CHR 4, 129759716   0.0069                                
  rs13148510           cg26766900         CHR 4, 129730719   0.0351             
  cg11264547           CHR 4, 129731973   0.0399                                
  rs13143771           cg19120496         CHR 4, 129731335   0.0100             
  cg26347359           CHR 4, 129759716   0.0095                                
  rs13142964           cg19120496         CHR 4, 129731335   0.0128             
  rs11722830 ^d^       cg14617908         CHR 4, 129730872   0.0139             
  cg09164670           CHR 4, 129731835   0.0133                                
  cg22868951           CHR 4, 129767588   0.0468                                
  rs12505447 ^d^       cg09164670         CHR 4, 129731835   0.0343             
  cg09568483           CHR 4, 129753010   0.0337                                
  rs6534704 ^d^        cg17503252         CHR 4, 129733028   0.0303             
  cg26347359           CHR 4, 129759716   0.0472                                
  *MYB*                rs210936           cg07363239         CHR 6, 135502390   0.0016
  cg11579069           CHR 6, 135502794   0.0187                                
  cg01369646           CHR 6, 135502875   0.0091                                
  rs17639758           cg18253802         CHR 6, 135501780   0.0411             
  rs1013891            cg00366934         CHR 6, 135503837   0.0471             
  cg10574148           CHR 6, 135504383   0.0117                                
  rs2179308            cg00366934         CHR 6, 135503837   0.0441             

The GLM procedure (SAS v9.2) adjusted for age, sex and BMI was used to test for the associations between tagged SNPs and methylation levels; ^a^ CpG site positions according to genome build 37; ^b^ *p* Values are derived from log10-transformed data; ^c^ Heterozygotes were merged with rare homozygotes (dominant model); ^d^ GWAS hit identified in the *FAS* study; ^e^ SNP showed genotype or gene-diet interaction effects on plasma triglyceride levels. \* *p* Value remained significant after controlling for false discovery rate (MULTTEST procedure, SAS v9.2).

ijms-18-00257-t005_Table 5

###### 

Marginal and significant correlations between transcript expression and DNA methylation levels (*n* = 29 individuals).

  Gene             Transcript       CpG Site      *p* Value
  ---------------- ---------------- ------------- -----------
  *IQCJ*           NM_001042706.1   cg034455716   0.0936
  NM_001042705.1   cg15736726       0.0230        
  cg23982461       0.0141                         
  *NXPH1*          NM_152745.2      cg0212438     0.0696
  cg06328127       0.0446                         
  *PHF17*          NM_024900.3      cg26766900    0.0937
  cg04482257       0.0050                         
  cg00296291       0.0953                         
  cg12676803       0.0806                         
  cg26347359       0.0842                         
  cg27628849       0.0038                         
  cg17233452       0.0417                         
  *MYB*            NM_005375.2      cg13400176    0.0567
  cg01369646       0.0240                         
  cg02127509       0.0496                         

The CORR procedure (SAS v9.2) adjusted for age, sex and BMI was used to test for the correlations between transcript expression and CpG site methylation levels.
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###### 

Marginal and significant correlations between pre-supplementation triglyceride levels and DNA methylation levels (*n* = 35 individuals).

  Gene          CpG Site     *p* Value
  ------------- ------------ -----------
  *IQCJ*        cg09784347   0.0399
  cg034455716   0.0610       
  *NXPH1*       cg00852549   0.0459
  cg00399951    0.0404       
  cg20378002    0.0368       
  *PHF17*       cg15389440   0.0070
  cg09863040    0.0317       
  cg12832492    0.0050       
  cg22922695    0.0686       
  cg09884389    0.0629       
  cg12204423    0.0943       
  cg01223512    0.0424       
  *MYB*         cg18253802   0.0134
  cg07363239    0.0407       

The CORR procedure (SAS v9.2) adjusted for age, sex and BMI was used to test for the correlations between transcript expression and CpG site methylation levels.
